1. De Novo Design of Self-Assembling Foldamers That Inhibit Heparin–Protein Interactions
- Author
-
Richard W. Scott, Jun Wang, Emma Magavern, Trevor M. Young, Michael J. Costanzo, Dylan J. Clements, William F. DeGrado, Robert W. Kavash, Katie B. Freeman, Dahui Liu, Yao Zhang, and Geronda L. Montalvo
- Subjects
Protein Conformation ,Stereochemistry ,medicine.drug_class ,Carboxamide ,010402 general chemistry ,Models, Biological ,01 natural sciences ,Biochemistry ,Inhibitory Concentration 50 ,Protein structure ,Fibrinolytic Agents ,medicine ,Side chain ,Dose-Response Relationship, Drug ,Molecular Structure ,Heparin ,010405 organic chemistry ,Chemistry ,Circular Dichroism ,Antithrombin ,Foldamer ,Articles ,General Medicine ,0104 chemical sciences ,Ionic strength ,Drug Design ,Molecular Medicine ,Fibrinolytic agent ,Protein Binding ,medicine.drug - Abstract
A series of self-associating foldamers have been designed as heparin reversal agents, as antidotes to prevent bleeding due to this potent antithrombotic agent. The foldamers have a repeating sequence of Lys-Sal, in which Sal is 5-amino-2-methoxy-benzoic acid. These foldamers are designed to self-associate along one face of an extended chain in a β-sheet-like interaction. The methoxy groups were included to form intramolecular hydrogen bonds that preclude the formation of very large amyloid-like aggregates, while the positively charged Lys side chains were introduced to interact electrostatically with the highly anionic heparin polymer. The prototype compound (Lys-Sal)4 carboxamide weakly associates in aqueous solution at physiological salt concentration in a monomer-dimer-hexamer equilibrium. The association is greatly enhanced at either high ionic strength or in the presence of a heparin derivative, which is bound tightly. Variants of this foldamer are active in an antithrombin III-factor Xa assay, showing their potential as heparin reversal agents.
- Published
- 2014
- Full Text
- View/download PDF